Substandard and Falsified Medicines: Proposed Methods for Case Finding and Sentinel Surveillance (Preprint)
Preprint
- 1 April 2021
- preprint
- Published by JMIR Publications Inc. in JMIR Preprints
Abstract
UNSTRUCTURED The World Health Organization and others warn that substandard and falsified medicines harm health and waste money, especially in low- and middle-income countries. However, no country has measured the market-wide extent of the problem, and no standardized methods exist to estimate the prevalence of either substandard or falsified medicines. This is, in part, because the task seems overwhelming; medicine markets are huge and diverse, and testing medicines is expensive. Many countries do operate some form of postmarket surveillance of medicine, but their methods and goals differ. There is currently no clear guidance on which surveillance method is most appropriate to meet specific public health goals. In this viewpoint, we aimed to discuss the utility of both case finding and risk-based sentinel surveillance for substandard and falsified medicines, linking each to specific public health goals. We posit that choosing the system most appropriate to the goal, as well as implementing it with a clear understanding of the factors driving the production and sale of substandard and falsified medicines, will allow for surveillance resources to be concentrated most efficiently. We adapted principles used for disease outbreak responses to suggest a case-finding system that uses secondary data to flag poor-quality medicines, proposing risk-based indicators that differ for substandard and falsified medicines. This system potentially offers a cost-effective way of identifying “cases” for market withdrawal, enhanced oversight, or another immediate response. We further proposed a risk-based sentinel surveillance system that concentrates resources on measuring the prevalence of substandard and falsified medicines in the risk clusters where they are most likely to be found. The sentinel surveillance system provides base data for a transparent, spreadsheet-based model for estimating the national prevalence of substandard and falsified medicines. The methods we proposed are based on ongoing work in Indonesia, a large and diverse middle-income country currently aiming to achieve universal health coverage. Both the case finding and the sentinel surveillance system are designed to be adaptable to other resource-constrained settings.Keywords
All Related Versions
- Published version: JMIR Public Health and Surveillance, 7 (8), e29309.
This publication has 24 references indexed in Scilit:
- Sweden, the first country to achieve the Joint United Nations Programme on HIV/AIDS (UNAIDS)/World Health Organization (WHO) 90‐90‐90 continuum of HIV care targetsHIV Medicine, 2016
- Public health interventions to protect against falsified medicines: a systematic review of international, national and local policiesHealth Policy and Planning, 2016
- A Repeat Random Survey of the Prevalence of Falsified and Substandard Antimalarials in the Lao PDR: A Change for the BetterThe American Journal of Tropical Medicine and Hygiene, 2015
- Substandard drugs: a potential crisis for public healthBritish Journal of Clinical Pharmacology, 2013
- The Past, Present, and Future of Public Health SurveillanceScientifica, 2012
- Guidelines for Field Surveys of the Quality of Medicines: A ProposalPLOS Medicine, 2009
- The Wisdom of Whores: Bureaucrats, Brothels, and the Business of AIDSJournal of the Association of Nurses in AIDS Care, 2009
- Chapter 53. Public Health Surveillance: A Tool for Targeting and Monitoring Interventions2006
- Lessons for surveillance in the 21st century: A historical perspective from the past five millenniaInternational Journal of Public Health, 2001
- HIV surveillance in hard-to-reach populationsAIDS, 2001